Pharma, Biotech, and CRO Consulting Services
Cagley Johnson Consulting Inc. (CJC)
greg@cagleyjohnson.com
leslie@cagleyjohnson.com
+1 (250) 516-3153
— Cagley Johnson Consulting Inc. (@cagleyjohnson) May 16, 2024
— Cagley Johnson Consulting Inc. (@cagleyjohnson) May 10, 2024
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations, and body weight than placebo at 1 year. View the full STEP-HFpEF DM trial: https://t.co/TbIZ7t391g pic.twitter.com/QDFFPw73RG
— NEJM (@NEJM) April 24, 2024